Publications

Selected Recent Publications

• Papachristodoulou, A., Heidegger, I., Virk, R. K., Di Bernardo, M., Kim, J. Y., Laplaca, C., Picech, F., Schäfer, G., De Castro, G. L., Hibshoosh, H., Loda, M., Klocker, H., Rubin, M. A., Zheng, T., Benson, M. C., McKiernan, J. M., Dutta, A., and Abate-Shen, C. (2023). Metformin overcomes the consequences of NKX3.1 loss to suppress prostate cancer progression. European Urology Aug. 31: S0302-2838(23)03016-6/. doi: 10.1016/j.eururo.2023.07.016. PMID: 37659962. 

• Vasciaveo, A., Arriaga, J.M., Nunes de Almeida, F., Zou, M., Douglass, E.F., Picech, F., Shibata, M., Rodriguez-Calero, A., de Brot, S., Mitrofanova, A., Chua, C.W., Karan, C., Realubit, R., Pampou, S., Kim, J.Y., Afari, S.N., Mukhammadov, T., Zanella, L., Corey, E., Alvarez, M.J., Rubin, M.A., Shen, M.M., Califano, A., Abate-Shen, C. (2023). OncoLoop: A network-based precision cancer medicine framework. Cancer Discov, 13 (2): 386–409. DOI: 10.1158/2159-8290.CD-22-0342.

• Park, S., Rong, L., Owczarek, T.B., Di Bernardo, M., Shoulson, R.L., Wai Chua, C., Kim, J.Y. Lankarani, A., Chakrapani, P.,  Syed, T., McKiernan, J.M., Solit, D.B., Shen, M.M., Al-Ahmadie, H., and Abate-Shen, C. (2021). Novel mouse models of bladder cancer identify a prognostic signature associated with risk of disease progression. Cancer Research. DOI: 10.1158/0008-5472.CAN-21-1254.

• Papachristodoulou, A., Rodriguez-Calero, A., Panja, S., Margolskee, E., Virk, R. K., Milner, T. A., Pina Martina, L., Kim, J. Y., Di Bernardo, M., Williams, A. B., Maliza, E. A., Caputo, J. M., Haas, C., Wang, V., De Castro, G. J., Wenske, S., Hibshoosh, H., McKiernan, J. M., Shen, M. M., Rubin, M. A., Mitrofanova, A., Dutta, A., and Abate-Shen, C. (2021). NKX3.1 localization to mitochondria suppresses prostate cancer initiation. Cancer Discov. 2021 Sep;11(9):2316-2333. PMID: 33893149.

• Arriaga, J. M., Panja, S., Alshalalfa, M., Zhao, J., Zou, M., Giacobbe, A., Madubata, C. J., Kim, J. Y., Rodriguez, A., Coleman, I., Virk, R., Hibshoosh, H., Ertunc, O., Oznek, B., Fountain, J., Karnes, R. J., Luo, J., Antonarakis, E. S., Nelson, P., Feng, F. Y., Rubin, M. A., De Marzo, A. M., Rabadan, R., Sims, P. A., Mitrofanova, A., and Abate-Shen, C.(2020). A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. Nature Cancer. PMCID: PMC8171279.

• Aytes, A., Giacobbe, A., Mitrofanova, A., Ruggero, K., Cyrta, J., Arriaga, J., Palomero, L., Farran-Matas, S., Rubin, M.A., Shen, M.M., Califano, C., and Abate-Shen, C. (2018). NSD2 is a conserved driver of metastatic prostate cancer progression. Nature Communications, 9:5201-5215. PMCID: PMC6281610.

• Zou, M., Toivanen, R., Mitrofanova, A. Floch, N., Hayati, S., Sun, S., Le Magnen, C., Chester, D., Mostaghel, E.A., Califano A, Rubin, M.A., Shen, M.M.*, and Abate-Shen, C.* (2017) Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer. Cancer Discovery, 7: 736-749. (*co-corresponding) PMCID: PMC5501744.

• Le Magnen, C., Virk, R.K, Dutta, A., Kim, J.Y., Panja, S., Lopez-Bujanda, Z.A., Califano, A., Drake, C.G., Mitrofanova, A., and Abate-Shen, C. (2018.) Cooperation of loss of NKX3.1 and inflammation in prostate cancer initiation. Disease Models and Mechanisms, Epub 2018/09/30. PMID: 30266798.

• Dutta, A., Panja,S., Virk, R.K., Kim, J.Y., Zott, R., Cremers, S., Golombos, D. M., Liu, D., Mosquera, J.M., Mostaghel, E.A., Barbieri, C.E., Mitrofanova, A.M., and Abate-Shen, C. (2017) Co-clinical analysis of a genetically-engineered mouse model and human prostate cancer reveals significance of NKX3.1 expression for response to 5α-reductase inhibition. European Urology, 72: 499-506. PMCID: PMC5600823.

• Dutta, A., Le Magnen, C., Mitrofanova, A., Ouyang, X., Califano, A., and Abate-Shen, C. (2016) Identification of an NKX3.1-G9a-UTY transcriptional regulatory network that controls prostate differentiation. Science 352: 1576-1580. PMCID: PMC5507586

Selected Reviews and Commentaries

• Papachristodoulou, A. and Abate-Shen, C. (2022). Precision intervention for prostate cancer: Re-evaluating who is at risk. Cancer Lett. 538: 215709. PMID: 35490919.
• Giacobbe, A. and Abate-Shen, C. (2021). Modeling metastasis in mice: a closer look. Trends in Cancer. DOI: https://doi.org/10.1016/j.trecan.2021.06.010.
• Arriaga, J.M. and Abate-Shen, C. (2019). Genetically-engineered mouse models of prostate cancer in the post-genomic era. Cold Spring Harb Perspect Med, in press. Epub 2018/04/18. PMID: 29661807.
• Le Magnen, C. Shen, MM, and Abate-Shen, C. (2018). Lineage plasticity in cancer progression and treatment. Annual Review of Cancer Biology. 2: 271-289. PMCID: PMC5942183.
• Le Magnen, C., Dutta, A., and Abate-Shen, C. (2016). Optimizing mouse models for precision cancer prevention. Nat. Rev. Cancer 16: 187-196. PMCID: PMC5517771
• Kobayashi, T., Owczarek, T.B., McKiernan, J.M., and Abate-Shen, C. (2015). Modeling bladder cancer in mice: opportunities and challenges. Nat. Rev. Cancer 15: 42-54. PMCID: PMC4386904.
• Shen, M.M., and Abate-Shen, C. (2010). Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 24:1967-2000. PMCID: PMC2939361.
• Abate-Shen, C. (2002). Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer 2(10): 777-785. PMID: 12360280
• Abate-Shen, C., and Shen, M. (2000). Molecular genetics of prostate cancer. Genes Dev. 14:2410-2434. PMID: 11018010.

Complete List of Published Work

https://www.ncbi.nlm.nih.gov/myncbi/cory.abate-shen.1/bibliography/public/